Table 1.

Baseline demographic and clinical characteristics at the time of initiation of HAART of patients exposed to Mycobacterium avium complex infection (MAC+) and matched patients unexposed to MAC infection (MAC−). ANRS Co3 Aquitaine Cohort.

	MAC+(N=51)		MAC− (N=145)

	N or median	% or IQR	N or median	% or IQR	p value
Age (years)	37	32; 49	37	33; 43	0.74
Male gender	39	76.5	115	79.3	0.67
HIV transmission group
Intravenous Drug Users	14	27.4	43	29.7	0.91
Men who have sex with men	21	41.2	47	32.4
Heterosexuals	11	21.6	39	26.9
Others	5	9.8	16	11.0
Baseline calendar period
[06/03/1995–31/12/1999]	42	82.4	118	81.4	0.88
[01/01/2000–13/05/2003]	9	17.6	27	18.6
Clinical stage
A	2	3.9	4	2.7	0.88
B	7	13.7	20	13.8
C	42	82.4	121	83.4

Treatments

Number of treatment regimens before HAART initiation^*
None (naïve patients)	17	33.3	46	31.7	0.98
Between 1 and 4 regimens	19	37.3	57	39.3
More than 4 regimens	15	29.4	42	29.0
Treatment regimen at HAART initiation
2 NRTIs and 1 PI	45	88.2	134	91.8	0.13
2 NRTIs and 1 NNRTI	2	3.9	8	6.2
3 NRTIs	4	7.9	2	1.3
2 NRTIs and 1 PI and 1 NNRTI	0	0.0	1	0.7
MAC prophylaxis
Clarithromycin	0	0.0	1	0.7	0.53
Azithromycin	0	0.0	4	2.8
Rifabutin	9	17.6	35	24.1

Biological characteristics at HAART initiation

Plasma HIV RNA (log₁₀ copies/mL)	5.3	4.4; 5.6	5.1	4.2; 5.5	0.22
T Lymphocytes CD4+ count (cells/mm³)	11	3; 38	16	8; 39	0.15
T Lymphocytes CD8+ count (cells/mm³)	359	206; 576	386	215; 634	0.39
Total lymphocytes (cells/mm³)	488	396; 858	688	410; 1065	0.09
Haemoglobinemia (g/dl)	11.5	9.8; 13.3	12.0	10.6; 13.0	0.23
Platelets (10³/mm³)	177	143; 230	157	119; 214	0.09

IQR: interquartile range; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor

A modification of at least one drug defined a new regimen